300255 常山药业
已收盘 07-06 15:00:00
资讯
新帖
简况
常山药业(300255)披露证券事务代表辞职公告,7月3日股价上涨2.55%
证券之星 · 07-03
常山药业(300255)披露证券事务代表辞职公告,7月3日股价上涨2.55%
7月1日常山药业涨7.13%,创业板医药ETF国泰基金重仓该股
证券之星 · 07-01
7月1日常山药业涨7.13%,创业板医药ETF国泰基金重仓该股
常山药业:阿贝那肽仍然在CDE在审目录之中
证券之星 · 07-01
常山药业:阿贝那肽仍然在CDE在审目录之中
常山药业:公司董事长从未质押过公司股票
证券之星 · 07-01
常山药业:公司董事长从未质押过公司股票
6月29日常山药业涨7.01%,创业板医药ETF国泰基金重仓该股
证券之星 · 06-29
6月29日常山药业涨7.01%,创业板医药ETF国泰基金重仓该股
常山药业:公司目前没有布局AI类业务
证券之星 · 06-26
常山药业:公司目前没有布局AI类业务
常山药业:上述信息不属实
证券之星 · 06-26
常山药业:上述信息不属实
常山药业:公司创新药CSCJC3456正在开展I期临床试验
证券之星 · 06-26
常山药业:公司创新药CSCJC3456正在开展I期临床试验
常山药业:公司目前未向药审中心提出药品试验数据保护申请
证券之星 · 06-24
常山药业:公司目前未向药审中心提出药品试验数据保护申请
常山药业:公司正在根据审评要求积极推进补充资料工作
证券之星 · 06-24
常山药业:公司正在根据审评要求积极推进补充资料工作
常山药业:艾本那肽用于减重适应症的Ⅰ期临床试验,目前正在有序推进中
证券之星 · 06-24
常山药业:艾本那肽用于减重适应症的Ⅰ期临床试验,目前正在有序推进中
常山药业(300255)披露为全资子公司提供担保进展公告,6月23日股价上涨1.13%
证券之星 · 06-23
常山药业(300255)披露为全资子公司提供担保进展公告,6月23日股价上涨1.13%
每周股票复盘:常山药业(300255)因股价大跌登龙虎榜
证券之星 · 06-21
每周股票复盘:常山药业(300255)因股价大跌登龙虎榜
6月17日常山药业(300255)龙虎榜数据:机构净买入2388.57万元,北向资金净买入4154.94万元
证券之星 · 06-17
6月17日常山药业(300255)龙虎榜数据:机构净买入2388.57万元,北向资金净买入4154.94万元
6月17日常山药业跌15.15%,创业板医药ETF国泰基金重仓该股
证券之星 · 06-17
6月17日常山药业跌15.15%,创业板医药ETF国泰基金重仓该股
常山药业:股东协议转让公司股份事项,对公司生产经营没有影响
证券之星 · 06-16
常山药业:股东协议转让公司股份事项,对公司生产经营没有影响
常山药业:公司本次需要补充艾本那肽上市审评需要的资料
证券之星 · 06-16
常山药业:公司本次需要补充艾本那肽上市审评需要的资料
6月15日常山药业跌14.05%,创业板医药ETF国泰基金重仓该股
证券之星 · 06-15
6月15日常山药业跌14.05%,创业板医药ETF国泰基金重仓该股
6月11日常山药业跌6.88%,创业板医药ETF国泰基金重仓该股
证券之星 · 06-11
6月11日常山药业跌6.88%,创业板医药ETF国泰基金重仓该股
6月9日常山药业涨7.65%,创业板医药ETF国泰基金重仓该股
证券之星 · 06-09
6月9日常山药业涨7.65%,创业板医药ETF国泰基金重仓该股
暂无数据
公司概况
公司名称:
河北常山生化药业股份有限公司
所属行业:
医药制造业
上市日期:
2011-08-19
主营业务:
河北常山生化药业股份有限公司的主营业务是肝素系列产品的研发、生产和销售。公司的主要产品是普通肝素原料药、低分子肝素原料药、低分子肝素制剂、普通肝素制剂。公司近几年分别被认定为国家企业技术中心、中国创业创新典型示范企业、河北省A级研发中心、国家级高新技术企业、国家地方工程实验室、河北省多糖类药物工程技术研究中心、河北省出口名牌等,建立了国家级博士后科研工作站,有效推动公司高级人才引进和创新驱动发展。
发行价格:
28.00
{"stockData":{"symbol":"300255","market":"SZ","secType":"STK","nameCN":"常山药业","latestPrice":24.81,"timestamp":1783321434000,"preClose":25.31,"halted":0,"volume":47790147,"delay":0,"changeRate":-0.0198,"floatShares":918000000,"shares":919000000,"eps":-0.3872,"marketStatus":"已收盘","change":-0.5,"latestTime":"07-06 15:00:00","open":25,"high":26.15,"low":24.58,"amount":1214000000,"amplitude":0.062,"askPrice":24.82,"askSize":138,"bidPrice":24.81,"bidSize":279,"shortable":0,"etf":0,"ttmEps":-0.3872,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783387800000},"marketStatusCode":5,"adr":0,"adjPreClose":25.31,"symbolType":"stock","openAndCloseTimeList":[[1783301400000,1783308600000],[1783314000000,1783321200000]],"highLimit":27.84,"lowLimit":22.78,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":919060878,"isCdr":false,"pbRate":19.22,"roa":"--","roe":"0.49%","epsLYR":-0.39,"committee":0.651782,"marketValue":22802000000,"turnoverRate":0.0521,"status":1,"floatMarketCap":22766000000},"requestUrl":"/m/hq/s/300255/tweets","defaultTab":"tweets","newsList":[{"id":"2648661105","title":"常山药业(300255)披露证券事务代表辞职公告,7月3日股价上涨2.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648661105","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648661105?lang=zh_cn&edition=full","pubTime":"2026-07-03 22:16","pubTimestamp":1783088186,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘,常山药业报收于25.31元,较前一交易日上涨2.55%,最新总市值为232.61亿元。近日,河北常山生化药业股份有限公司收到证券事务代表白荣国先生的书面辞职报告,其因个人原因申请辞去公司证券事务代表职务,辞职报告自送达董事会之日起生效,辞职后不再担任公司任何职务。白荣国先生在任职期间恪尽职守,公司董事会对其表示感谢。公司将根据相关规定尽快聘任新的证券事务代表。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300045622.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300255","161027","BK0239","BK0172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648516989","title":"7月1日常山药业涨7.13%,创业板医药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648516989","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648516989?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:51","pubTimestamp":1782895889,"startTime":"0","endTime":"0","summary":"证券之星消息,7月1日常山药业涨7.13%,收盘报25.09元,换手率5.11%,成交量46.93万手,成交额11.28亿元。重仓常山药业的公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为国泰基金的创业板医药ETF国泰。创业板医药ETF国泰的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100031673.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255","BK0239","BK0172","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648518315","title":"常山药业:阿贝那肽仍然在CDE在审目录之中","url":"https://stock-news.laohu8.com/highlight/detail?id=2648518315","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648518315?lang=zh_cn&edition=full","pubTime":"2026-07-01 15:06","pubTimestamp":1782889579,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业(300255)07月01日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘,阿贝那肽是否符合今年国谈医保申报的资格?公司有没有申报?常山药业回复:尊敬的投资者,您好!按照国家医保局的文件要求,进入2026年国家医保目录调整的条件是7月3日前补充提交相关上市证明材料,目前阿贝那肽仍然在CDE在审目录之中,公司仍在积极有序推进资料补充工作。感谢您的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100023593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0172","BK0239","300255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648518582","title":"常山药业:公司董事长从未质押过公司股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2648518582","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648518582?lang=zh_cn&edition=full","pubTime":"2026-07-01 15:00","pubTimestamp":1782889243,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业07月01日在投资者关系平台上答复投资者关心的问题。目前公司控股股东的质押风险可控。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100023520.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0172","BK0070","BK0239","300255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647651322","title":"6月29日常山药业涨7.01%,创业板医药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647651322","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647651322?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:45","pubTimestamp":1782722720,"startTime":"0","endTime":"0","summary":"证券之星消息,6月29日常山药业涨7.01%创60日新低,收盘报24.41元,换手率6.88%,成交量63.15万手,成交额15.15亿元。重仓常山药业的公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为国泰基金的创业板医药ETF国泰。创业板医药ETF国泰的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024655.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0172","300255","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646357051","title":"常山药业:公司目前没有布局AI类业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2646357051","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646357051?lang=zh_cn&edition=full","pubTime":"2026-06-26 20:53","pubTimestamp":1782478387,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业(300255)06月26日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好,请问公司是否布局AI医药、AI药物研发相关业务?有无自研AI药物研发平台?常山药业回复:尊敬的投资者,您好!公司目前没有布局AI类业务。感谢您的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600042732.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300255","BK0070","BK0172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646333726","title":"常山药业:上述信息不属实","url":"https://stock-news.laohu8.com/highlight/detail?id=2646333726","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646333726?lang=zh_cn&edition=full","pubTime":"2026-06-26 11:34","pubTimestamp":1782444884,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业(300255)06月26日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好,网传公司自研“神农大脑”AI研发平台是否属实?该平台目前落地应用情况如何?公司CSCJC3456抗肿瘤1类新药,前期靶点发现、分子结构筛选是否使用AI算法辅助完成?常山药业回复:尊敬的投资者,您好!上述信息不属实,请投资者理性甄别网络传言,以公司官方渠道披露的公告信息为准。感谢您的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600018291.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255","BK0172","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646333777","title":"常山药业:公司创新药CSCJC3456正在开展I期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2646333777","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646333777?lang=zh_cn&edition=full","pubTime":"2026-06-26 11:34","pubTimestamp":1782444883,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业06月26日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好,请问CSCJC3456是否做完I期后直接进入IIb注册临床、跳过IIa期试验?公司创新药CSCJC3456正在开展I期临床试验。公司将在I期临床试验结果达到预期后,与相关监管机构和医学专家沟通评估,确认后续临床试验方案,目前无法准确预估后续时间和进度。公司始终积极推进创新药研发相关工作,并将及时根据临床进展依规履行信息披露义务,请投资者理性投资!","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600018289.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK1161","06978","159992","BK0172","BK1574","BK0239","300255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645860335","title":"常山药业:公司目前未向药审中心提出药品试验数据保护申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2645860335","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645860335?lang=zh_cn&edition=full","pubTime":"2026-06-24 15:07","pubTimestamp":1782284835,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业(300255)06月24日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘好,请问艾本那肽的数据保护申请是否已提交给审评中心?数据保护申请的初步审核是否已在进行中?常山药业回复:尊敬的投资者,您好!公司目前未向药审中心提出药品试验数据保护申请。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400022170.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300255","BK0239","BK0172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645486772","title":"常山药业:公司正在根据审评要求积极推进补充资料工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2645486772","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645486772?lang=zh_cn&edition=full","pubTime":"2026-06-24 15:00","pubTimestamp":1782284452,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业06月24日在投资者关系平台上答复投资者关心的问题。公司正在全力推进相关工作,后续进展公司将根据信息披露规则,依规及时披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400022095.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0172","300255","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645677558","title":"常山药业:艾本那肽用于减重适应症的Ⅰ期临床试验,目前正在有序推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2645677558","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645677558?lang=zh_cn&edition=full","pubTime":"2026-06-24 15:00","pubTimestamp":1782284451,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业06月24日在投资者关系平台上答复投资者关心的问题。临床试验招募工作是否正式开启?公司艾本那肽用于减重适应症的Ⅰ期临床试验,目前正在有序推进中,尚未完成首例受试者入组。公司始终稳步推进相关临床试验筹备工作,后续将根据项目进展实际情况,依据信披规则及时履行披露义务,请您继续关注公司官方渠道发布的信息。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400022094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","300255","BK0172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645340248","title":"常山药业(300255)披露为全资子公司提供担保进展公告,6月23日股价上涨1.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645340248","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645340248?lang=zh_cn&edition=full","pubTime":"2026-06-23 22:04","pubTimestamp":1782223486,"startTime":"0","endTime":"0","summary":"截至2026年6月23日收盘,常山药业报收于26.76元,较前一交易日上涨1.13%,最新总市值为245.94亿元。近日,河北常山生化药业股份有限公司披露《关于为全资子公司提供担保的进展公告》。截至公告日,公司及控股子公司实际担保余额为12.97亿元,占最近一期经审计净资产的107.68%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300042026.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0172","BK0239","300255","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645093036","title":"每周股票复盘:常山药业(300255)因股价大跌登龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2645093036","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645093036?lang=zh_cn&edition=full","pubTime":"2026-06-21 01:14","pubTimestamp":1781975652,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘,常山药业报收于25.85元,较上周的35.29元下跌26.75%。本周,常山药业6月15日盘中最高价报33.16元。本周关注点来自交易信息汇总:常山药业因日跌幅达15%及三日累计偏离值超30%登龙虎榜。河北常山生化药业股份有限公司股票连续三个交易日收盘价格跌幅偏离值累计超过30%,构成股票交易异常波动。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062100000116.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0172","BK0239","300255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644712238","title":"6月17日常山药业(300255)龙虎榜数据:机构净买入2388.57万元,北向资金净买入4154.94万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2644712238","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644712238?lang=zh_cn&edition=full","pubTime":"2026-06-17 17:32","pubTimestamp":1781688741,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2026年6月17日公布的交易公开信息显示,常山药业因日跌幅达到15%的前5只证券,连续三个交易日内,跌幅偏离值累计达到30%的证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年6月17日收盘,常山药业报收于24.92元,下跌15.15%,换手率7.83%,成交量71.89万手,成交额18.98亿元。从龙虎榜公布的当日买卖数据来看,机构合计净买入2388.57万元,北向资金合计净买入4154.94万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700030414.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0172","BK0239","300255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644143537","title":"6月17日常山药业跌15.15%,创业板医药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2644143537","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644143537?lang=zh_cn&edition=full","pubTime":"2026-06-17 16:39","pubTimestamp":1781685559,"startTime":"0","endTime":"0","summary":"证券之星消息,6月17日常山药业跌15.15%创60日新低,收盘报24.92元,换手率7.83%,成交量71.89万手,成交额18.98亿元。重仓常山药业的公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为国泰基金的创业板医药ETF国泰。创业板医药ETF国泰的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700028086.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0172","300255","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643733922","title":"常山药业:股东协议转让公司股份事项,对公司生产经营没有影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2643733922","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643733922?lang=zh_cn&edition=full","pubTime":"2026-06-16 11:36","pubTimestamp":1781580980,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业(300255)06月16日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的刘董秘,元素基金转让对公司经营有没有正向影响?常山药业回复:你好!股东协议转让公司股份事项,对公司生产经营没有影响。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600017518.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255","BK0172","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643733932","title":"常山药业:公司本次需要补充艾本那肽上市审评需要的资料","url":"https://stock-news.laohu8.com/highlight/detail?id=2643733932","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643733932?lang=zh_cn&edition=full","pubTime":"2026-06-16 11:33","pubTimestamp":1781580794,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业06月16日在投资者关系平台上答复投资者关心的问题。公司本次需要补充艾本那肽上市审评需要的资料,属于药品专业技术方面的内容,与药品包装、名称等无关,公司不方便公布具体的补充资料内容,敬请谅解。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600017311.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","300255","BK0172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643727967","title":"6月15日常山药业跌14.05%,创业板医药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2643727967","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643727967?lang=zh_cn&edition=full","pubTime":"2026-06-15 16:48","pubTimestamp":1781513332,"startTime":"0","endTime":"0","summary":"证券之星消息,6月15日常山药业跌14.05%创60日新低,收盘报30.33元,换手率4.1%,成交量37.61万手,成交额11.75亿元。重仓常山药业的公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为国泰基金的创业板医药ETF国泰。创业板医药ETF国泰的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500020385.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0172","300255","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642238407","title":"6月11日常山药业跌6.88%,创业板医药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642238407","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642238407?lang=zh_cn&edition=full","pubTime":"2026-06-11 16:32","pubTimestamp":1781166769,"startTime":"0","endTime":"0","summary":"证券之星消息,6月11日常山药业跌6.88%创60日新低,收盘报34.91元,换手率2.2%,成交量20.23万手,成交额7.19亿元。重仓常山药业的公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为国泰基金的创业板医药ETF国泰。创业板医药ETF国泰的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100025677.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["160219","300255","BK0172","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642463726","title":"6月9日常山药业涨7.65%,创业板医药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642463726","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642463726?lang=zh_cn&edition=full","pubTime":"2026-06-09 16:51","pubTimestamp":1780995061,"startTime":"0","endTime":"0","summary":"证券之星消息,6月9日常山药业涨7.65%,收盘报39.8元,换手率3.38%,成交量30.97万手,成交额12.46亿元。重仓常山药业的公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为国泰基金的创业板医药ETF国泰。创业板医药ETF国泰的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060900027277.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300255","BK0239","BK0172"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1783349881064,"stockEarnings":[{"period":"1week","weight":0.1096},{"period":"1month","weight":-0.3431},{"period":"3month","weight":-0.4125},{"period":"6month","weight":-0.5924},{"period":"1year","weight":-0.4497},{"period":"ytd","weight":-0.5924}],"compareEarnings":[{"period":"1week","weight":0.0041},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0421},{"period":"6month","weight":0.0188},{"period":"1year","weight":0.1683},{"period":"ytd","weight":0.0188}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"河北常山生化药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"52828人(较上一季度增加18.72%)","perCapita":"17370股","listingDate":"2011-08-19","address":"河北省石家庄市正定县中国(河北)自由贸易试验区正定片区高新技术产业开发区南区梦龙街71号","registeredCapital":"91906万元","survey":" 河北常山生化药业股份有限公司的主营业务是肝素系列产品的研发、生产和销售。公司的主要产品是普通肝素原料药、低分子肝素原料药、低分子肝素制剂、普通肝素制剂。公司近几年分别被认定为国家企业技术中心、中国创业创新典型示范企业、河北省A级研发中心、国家级高新技术企业、国家地方工程实验室、河北省多糖类药物工程技术研究中心、河北省出口名牌等,建立了国家级博士后科研工作站,有效推动公司高级人才引进和创新驱动发展。","listedPrice":28},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"常山药业(300255)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供常山药业(300255)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"常山药业,300255,常山药业股票,常山药业股票老虎,常山药业股票老虎国际,常山药业行情,常山药业股票行情,常山药业股价,常山药业股市,常山药业股票价格,常山药业股票交易,常山药业股票购买,常山药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"常山药业(300255)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供常山药业(300255)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}